Cassava Sciences, Inc. ($SAVA) Stock Forecast: Down 9.6% Today

What is Cassava Sciences, Inc.?

Cassava Sciences, Inc. (SAVA) is a pharmaceutical company focused on developing innovative treatments for Alzheimer's disease. The stock is listed on the NASDAQ.

Why is Cassava Sciences, Inc. going down?

SAVA stock is down 9.6% on Jan 8, 2025 15:18

• The downward movement in SAVA's stock today may be linked to multiple class action lawsuits related to alleged securities fraud against the company.
• Reports concerning the class action lawsuits might have sparked worries among investors regarding SAVA's financial practices and transparency, resulting in a sell-off of the stock.
• The approaching deadline for lead plaintiff applications in the lawsuits could have intensified pressure on the stock price as investors grappled with the legal uncertainties surrounding the company.
• Investors facing significant losses in SAVA may be weighing their choices in light of the legal issues, further impacting the stock's decline.

SAVA Price Chart

SAVA Technical Analysis

SAVA News

CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

NEW ORLEANS, Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Kahn Swick & Foti, LLC ( "KSF" ) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against ...

https://www.benzinga.com/pressreleases/25/01/g42865974/cassava-sciences-shareholder-alert-by-former-louisiana-attorney-general-kahn-swick-foti-llc-remind

Class Action Announcement for Cassava Sciences, Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Cassava Sciences, Inc. - Cassava Sciences ( NASDAQ:SAVA )

RADNOR, Pa., Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ( ...

https://www.benzinga.com/pressreleases/25/01/g42801453/class-action-announcement-for-cassava-sciences-inc-investors-a-securities-fraud-class-action-lawsu

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Cassava Sciences ( NASDAQ:SAVA )

NEW YORK, Jan. 01, 2025 ( GLOBE NEWSWIRE ) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ( "Cassava" or "the Company" ) SAVA and certain of its officers.

https://www.benzinga.com/pressreleases/25/01/g42757152/sava-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-cassava-sciences-inc-investors-w

Trending Today

XRP ($XRP) Crypto Forecast: Down 5.8% Today

Ethereum ($ETH) Crypto Forecast: Down 5.3% Today

Kusama ($KSM) Crypto Forecast: Down 8.7% Today

Aave ($AAVE) Crypto Forecast: Down 11.3% Today

Polkadot ($DOT) Crypto Forecast: Down 8.7% Today

Stellar ($XLM) Crypto Forecast: Down 6.8% Today

Solana ($SOL) Crypto Forecast: Down 5.4% Today

Cardano ($ADA) Crypto Forecast: Down 7.3% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.1% Today

Sui ($SUI) Crypto Forecast: Down 8.7% Today

Cassava Sciences, Inc. Price History

06.00.2025 - SAVA Stock was up 6.0%

• Today's uptick in SAVA's stock performance may be linked to recent developments concerning a class action lawsuit. Some investors appear to view this as a temporary challenge, sparking heightened buying interest.
• Market response also indicates a prevailing belief in Cassava Sciences, Inc.'s future potential, with legal issues seen as a minor obstacle in the company's growth path.
• The increased trading activity and positive price movements suggest that some traders perceive an opportunity to leverage the volatility surrounding SAVA's stock, potentially fueling further bullish momentum.

27.11.2024 - SAVA Stock was up 5.4%

• The bullish movement in SAVA's stock today could be attributed to the following factors:
• Despite the class action lawsuits and upcoming deadlines reminding investors of potential losses, the market might be reacting positively to any potential resolutions or developments in the company's legal issues.
• Investors may be optimistic about the company's future prospects, potentially driven by positive developments in its drug development pipeline or other strategic initiatives.
• Speculation or market sentiment could be driving the stock price up, as traders anticipate short-term gains or volatility in response to the legal challenges faced by the company.
• It's essential for investors to closely monitor any updates regarding the legal proceedings and the company's operational performance to make informed decisions about their investments in Cassava Sciences, Inc.

02.00.2025 - SAVA Stock was up 10.3%

• SAVA's stock experienced a bullish trend, possibly due to investors interpreting the class action lawsuit as a temporary setback rather than a long-term concern.
• The market's positive response to recent events may reflect investor confidence in Cassava Sciences' ability to manage legal challenges effectively.
• Some investors view the situation as a chance to purchase stocks at a lower price, particularly if they have faith in the company's long-term drug development plans despite legal uncertainties.
• Overall, the optimistic trend in SAVA's stock suggests that market sentiment remains resilient in light of the lawsuit news, indicating a degree of confidence in the stock's performance.

31.11.2024 - SAVA Stock was down 5.4%

• The bearish movement in SAVA's stock price could be attributed to the class action lawsuits recently filed against the company by law firms.
• Investors might be reacting negatively to the legal challenges and uncertainties surrounding Cassava Sciences, leading to a significant sell-off in the stock.
• The news of substantial losses and the opportunity for investors to lead class action lawsuits could have further fueled concerns and prompted a bearish sentiment in the market for SAVA today.

08.00.2025 - SAVA Stock was down 9.6%

• The downward movement in SAVA's stock today may be linked to multiple class action lawsuits related to alleged securities fraud against the company.
• Reports concerning the class action lawsuits might have sparked worries among investors regarding SAVA's financial practices and transparency, resulting in a sell-off of the stock.
• The approaching deadline for lead plaintiff applications in the lawsuits could have intensified pressure on the stock price as investors grappled with the legal uncertainties surrounding the company.
• Investors facing significant losses in SAVA may be weighing their choices in light of the legal issues, further impacting the stock's decline.

19.11.2024 - SAVA Stock was down 7.3%

• The decline in SAVA's stock today is connected to several class action lawsuits brought forth by shareholders, alleging securities law breaches and significant financial losses.
• The legal disputes and uncertainties linked to these lawsuits have likely caused apprehension and uncertainty among investors, resulting in the stock price decrease.
• Investors are paying close attention to the progress of these lawsuits and how they could potentially impact Cassava Sciences' upcoming operations and drug development efforts.

19.11.2024 - SAVA Stock was down 10.8%

• The bearish movement in SAVA stock today can be attributed to the series of class action lawsuits and legal challenges the company is facing. Here's a witty assessment of the situation:
• Investors in Cassava Sciences might be feeling more forgetful than Alzheimer's patients with the flurry of class action lawsuits reminding them of their losses.
• With legal battles piling up faster than clinical trial data, SAVA's stock took a nosedive as investors brace for potential financial implications.
• The market's reaction to the legal woes suggests that even in the world of pharmaceuticals, a bitter pill to swallow can come in the form of lawsuits, not just failed drug trials.

26.10.2024 - SAVA Stock was down 5.4%

• Cassava Sciences' stock plummeted over 80% after the company announced disappointing results from its Phase 3 trial for an Alzheimer's disease treatment.
• The negative outcome of the trial, where the drug failed to meet key endpoints, led to a significant sell-off by investors.
• Martin Shkreli's recommendation to 'short SAVA' likely exacerbated the stock's decline, adding to the bearish sentiment surrounding the company.
• The market's reaction to the news reflects the high stakes and volatility often associated with pharmaceutical companies, especially when pivotal studies do not yield positive results.

26.10.2024 - SAVA Stock was down 17.1%

• Cassava Sciences (SAVA) saw its stock drop by more than 80% due to the unsuccessful outcome of its Alzheimer's drug in a key Phase 3 trial.
• The bearish trend was worsened by negative comments from an individual known as 'Pharma Bro,' who suggested investors should consider shorting SAVA, foreseeing a crash.
• Analysts have revised their opinions on the stock, noting oversold conditions based on technical analysis, though a potential reversal could be on the horizon.
• Following the drug's failure in the advanced trial, further research was stopped, leading to a sharp stock price decrease as investors reassessed the company's potential in the Alzheimer's treatment sector.

26.10.2024 - SAVA Stock was down 5.1%

• SAVA stock plummeted by 84% in a significant downward movement today.
• The decline was driven by the disappointment surrounding Cassava Sciences' Alzheimer's drug during a late-stage study, where it failed to show a notable decrease in cognitive or functional deterioration.
• The adverse results of the drug trial caused a sharp drop in the stock value, extinguishing investor confidence and setting a bearish tone for the company.
• Despite recent technical signs of being oversold and potential hints of a reversal in trend, the substantial setback in the drug trial outcomes outweighed any positive outlook, leading to a dramatic fall in SAVA stock.

17.11.2024 - SAVA Stock was down 6.0%

• The bearish movement in SAVA's stock price can be attributed to the multiple class action lawsuits filed against the company for alleged securities law violations.
• Investors may have reacted negatively to the news of these lawsuits, causing a loss in confidence in the company's management and operations.
• The legal uncertainties surrounding Cassava Sciences, Inc. seem to have spooked investors, leading to a sell-off of the stock and driving the bearish trend in the market today.

23.11.2024 - SAVA Stock was up 6.0%

• Despite facing legal issues and alerts from investors, SAVA stock showed a bullish trend.
• The market's positive response could be linked to potential advancements in Cassava Sciences, Inc.'s drug pipeline or research efforts.
• Investors may be anticipating a favorable resolution to the legal disputes, resulting in increased buying interest.
• The stock's upward movement might also be influenced by improving market sentiment towards the company, potentially driven by positive analyst evaluations or strategic updates.